Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Patients must have pain present for more than 3 months after the healing of shingles skin rash.

• Patients at screening must have a score >=40 mm on the pain visual analogue scale.

Exclusion Criteria:

• Patients with poor renal function.

• Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.

• Patients with abnormal electrocardiogram.